Genoray Future Growth
Future criteria checks 0/6
Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Genoray.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Medical Equipment earnings growth | 42.3% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Why Genoray's (KOSDAQ:122310) Shaky Earnings Are Just The Beginning Of Its Problems
Mar 28
Does Genoray Co., Ltd. (KOSDAQ:122310) Have A Place In Your Dividend Portfolio?
Apr 12Does Genoray (KOSDAQ:122310) Have A Healthy Balance Sheet?
Mar 01We Like Genoray's (KOSDAQ:122310) Returns And Here's How They're Trending
Feb 11
Is Genoray Co., Ltd.'s (KOSDAQ:122310) Recent Performance Tethered To Its Attractive Financial Prospects?
Jan 27Is Genoray Co., Ltd. (KOSDAQ:122310) A Smart Choice For Dividend Investors?
Jan 12Genoray Co., Ltd. (KOSDAQ:122310) Looks Interesting, And It's About To Pay A Dividend
Dec 24A Look At The Fair Value Of Genoray Co., Ltd. (KOSDAQ:122310)
Dec 15We Think Genoray (KOSDAQ:122310) Can Stay On Top Of Its Debt
Nov 30In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Genoray has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2023 | 97,897 | 12,486 | -5,044 | 3,555 | N/A |
| 9/30/2023 | 92,300 | 12,794 | -12,765 | 3,170 | N/A |
| 6/30/2023 | 85,470 | 12,315 | -10,863 | 5,051 | N/A |
| 3/31/2023 | 83,225 | 12,945 | -1,344 | 13,170 | N/A |
| 12/31/2022 | 82,604 | 13,900 | 1,057 | 14,837 | N/A |
| 9/30/2022 | 83,336 | 14,874 | 15,209 | 21,454 | N/A |
| 6/30/2022 | 83,964 | 15,663 | 12,757 | 18,948 | N/A |
| 3/31/2022 | 78,643 | 14,745 | 9,234 | 16,289 | N/A |
| 12/31/2021 | 74,290 | 14,323 | 6,475 | 15,383 | N/A |
| 9/30/2021 | 64,502 | 11,057 | 3,695 | 11,903 | N/A |
| 6/30/2021 | 63,259 | 10,327 | 9,050 | 17,078 | N/A |
| 3/31/2021 | 62,145 | 10,007 | 4,675 | 11,571 | N/A |
| 12/31/2020 | 61,688 | 10,172 | 4,228 | 8,507 | N/A |
| 9/30/2020 | 67,862 | 13,260 | 5,177 | 9,567 | N/A |
| 6/30/2020 | 67,052 | 13,788 | 1,180 | 5,915 | N/A |
| 3/31/2020 | 66,469 | 14,142 | 5,679 | 10,566 | N/A |
| 12/31/2019 | 65,106 | 13,240 | 5,826 | 10,655 | N/A |
| 9/30/2019 | 59,345 | 11,859 | 3,448 | 8,047 | N/A |
| 6/30/2019 | 55,975 | 10,058 | 1,505 | 6,300 | N/A |
| 3/31/2019 | 56,567 | 9,659 | -14 | 4,688 | N/A |
| 12/31/2018 | 56,289 | 9,472 | 2,697 | 6,893 | N/A |
| 9/30/2018 | 53,189 | 8,323 | 1,513 | 5,697 | N/A |
| 6/30/2018 | 51,083 | 7,490 | 4,446 | 7,996 | N/A |
| 3/31/2018 | 46,055 | 5,741 | 3,396 | 6,450 | N/A |
| 12/31/2017 | 44,492 | 5,170 | 1,401 | 4,472 | N/A |
| 12/31/2016 | 38,278 | 3,225 | N/A | 3,473 | N/A |
| 12/31/2015 | 31,880 | 1,997 | N/A | 2,100 | N/A |
| 12/31/2014 | 28,569 | 956 | N/A | 3,272 | N/A |
| 12/31/2013 | 30,475 | 437 | N/A | 985 | N/A |
Analyst Future Growth Forecasts
Ingresos vs. tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de A122310 es superior a la tasa de ahorro (2.3%).
Beneficios frente mercado: Datos insuficientes para determinar si se prevé que los beneficios de A122310 crezcan más deprisa que el mercado KR
Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de A122310 crezcan significativamente en los próximos 3 años.
Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de A122310 crezcan más rápido que el mercado de KR.
Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de A122310 crezcan a un ritmo superior a 20% al año.
Earnings per Share Growth Forecasts
Future Return on Equity
Futura rentabilidad financiera (ROE): Datos insuficientes para determinar si la Rentabilidad de los fondos propios de A122310 se prevé elevada dentro de 3 años.